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Are Still Leaving to the Surgeons?
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Nowadays, development of new technologies is still ongoing with the ultimate goal of 
maximizing treatment outcomes with less invasiveness and reduced procedural risk. 
This review is intended to update on when interventionalists need surgical support in 
common or emerging problems in congenital heart disease.
Keywords: catheter intervention, surgical therapy, congenital heart disease, interventional cardiologist, 
collaboration
evOLUTiON OF TeCHNOLOGY FOR CATHeTeR iNTeRveNTiON 
MAKeS THe iMPOSSiBLeS POSSiBLe
During the last 60 years, medical engineering technology has helped to make important advances 
in transcatheter treatment of congenital and structural heart disease. Catheter-based therapy in 
congenital heart disease (CHD) became a reality in 1953 with the first description of pulmonary 
valvoplasty by Rubio-Alvarez et al. (1). Since then, balloon dilation has proved its efficacy (2, 3) and 
has become treatment of choice for pulmonary valve stenosis. The next paradigm shift of transcath-
eter CHD therapy was the novel approach of balloon atrial septostomy (BAS) for cyanotic patients 
with transposition of the great arteries (TGA) in 1966 by Rashkind and Miller (4). Later in the late 
1960s, the first percutaneous occlusion of patent ductus arteriosus (PDA) using Ivalon (polyvinyl 
alcohol) plug was reported (5). In the ensuing 10 years, transcatheter closure of atrial septal defect 
(ASD) became a reality with a specially designed Dacron-covered stainless steel umbrella device, 
reported by King & Mills (6). Thereafter, the 1980s was the era of stainless steel material for endovas-
cular stents and occlusion devices (7–9). In the early 1990s, laser and radiofrequency technologies 
became major contributors of balloon-assisted valvoplasty in pulmonary valve atresia (10). In the 
late 1990s, novel design of shape-memory devices made from a nickel and titanium (nitinol) metal 
alloy completely changed the way physicians treat common CHDs (11–13). Nitinol technology 
has also been used in self-expandable stent platforms for endovascular stents and percutaneous 
bioprosthesis valves (14, 15).
ATRiAL SePTOSTOMY
Percutaneous creation or enlargement of the interatrial communication is the earliest collaborations 
between interventionalist and surgeon in the history of CHD treatment. Over 50 years, BAS has been 
stabilizing hypercyanotic transposition of TGA babies prior to corrective surgical repair. However, 
from recent publications, 43–62% of the cases cannot discontinue prostaglandin E1 after the success-
ful BAS (16–18). Apart from enhancing the oxygenated–deoxygenated blood mixture, BAS remains 
indicate to augment cardiac output in patients with the right or left heart obstructions (e.g., tricuspid 
atresia, pulmonary valve atresia associated with RV coronary dependent circulation, mitral atresia, 
aortic atresia). The complications after BAS are unlikely to occur nowadays. These include balloon 
rupture, failure in balloon deflation, rupture of the atrial appendage, injury of cardiac structures, and 
FiGURe 1 | Angiogram in lateral projection of PDA closed by coil (A), 
Amplatzer Duct Occluder ii (ADOii) (B), and Occlutech Duct  
Occluder (C).
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transitory rhythm disturbances (19). Although various additional 
techniques have been developed over the years for creation or 
enlargement of the septum in complex anatomy (e.g., blade atrial 
septostomy, static balloon dilation, radiofrequency perforation 
or transeptal puncture, and stent implantation of the interatrial 
septum), the goal of these methods is a bridge to definite surgical 
treatment.
The majority of common CHDs are now treatable percute-
neously. However, surgery is still an option for many of these 
 common CHDs and surgeons are still needed to treat some of 
these defects.
PATeNT DUCTUS ARTeRiOSUS CLOSURe
Patent ductus arteriosus is one of the most common CHDs in 
all ages. Since the first report of transcatheter closure 50  years 
ago, currently, transcatheter PDA closure has become a widely 
accepted procedure worldwide with comparable results to surgi-
cal therapy (20, 21). Major adverse events of transcatheter PDA 
occlusion (i.e., device embolization, hemolysis, and obstruction 
of the left pulmonary artery/aortic isthmus) can occur with inci-
dence of 0.6–83.3% depending upon the selected device (18, 19). 
It is indicated for a symptomatic moderate to large PDA with left-
to-right shunt or previously known occurrence of endocarditis. 
However, for a small or silent PDA, transcatheter PDA closure 
may be considered in some countries and avoided in others (22). 
A variety of devices are available for closing PDAs (23, 24). These 
have their own advantages and disadvantages. In general, for 
a small PDA of <2  mm at its narrowest point, closure can be 
achieved with coils or the Amplatzer Duct Occluder II (ADOII; 
St Jude Medical, MN, USA) (Figures  1A,B). For a large PDA, 
the disk devices are preferred (Figure 1C). With custom-made 
disk devices, a duct of 16-mm diameter or more can be occluded 
successfully nowadays with a lower risk (25). In addition, with 
reduction of the delivery system from 18Fr (in 1967) to 3–4 Fr, the 
feasibility of transcatheter PDA closure is considerably improved, 
even in newborns (26, 27), and is associated with a shorter recov-
ery time than surgical ligation (28). However, percutaneous PDA 
closure in neonates and infants is an emerging field with some 
limitations of available devices and instruments. It seems to have 
relatively higher major adverse events than in older children (29). 
Therefore, the procedure has to be balanced with the experience 
of the operators and the capabilities of the unit, as surgical PDA 
ligation remains a standard and safe procedure in small babies 
(30). Further development of a robust device and delivery system 
that fits to a unique morphology of the duct in prematurity (31) 
will make transcatheter PDA closure become treatment of choice 
for symptomatic preterm and/or low-bodyweight infants in the 
near future.
ATRiAL SePTAL DeFeCT CLOSURe
Double-disk devices are now becoming universal for percu-
taneous closure of secundum ASDs (Figure  2). In common 
practice, patients with the body weight more than 15  kg who 
have hemodynamic significant secundum ASD and suitable 
anatomical features are indicated for percutaneous ASD closure 
(22). Transcatheter closure has shown comparable outcome to 
surgery in pediatric and adult patients, with low complication 
rates, short anesthetic times, and short hospitalization (32–34). 
However, once a complication occurs, it sometimes leads to 
urgent surgical treatment, which is then associated with a higher 
morbidity and mortality than elective surgical ASD closure (35). 
Complications after device implantation include device embo-
lization, cardiac perforation, thrombo-embolic events, cardiac 
arrhythmia, or significant residual shunt. Although the risk of 
long-term complications after device implantation is very low, 
several case reports and literature review have shown that these 
particular problems, such as erosions, may occur 8  years after 
the initial device closure (36, 37). Therefore, patient selection and 
comprehensive short- and long-term follow-up are necessary for 
FiGURe 2 | Fluoroscopic and echocardiographic pictures of various ASD devices. Amplatzer Septal Occluder (A), Occlutech Figulla Flex II Septal Occluder 
(B), and CeraFlex ASD Occluder (C).
FiGURe 3 | Angiographic pictures of the occlusion devices for 
perimembranous ventricular septal defect (pmvSD).
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all transcatheter ASD closure patients. There are some defects 
with deficient rims in more than one area or very large ASDs, 
which still require surgical treatment.
veNTRiCULAR SePTAL DeFeCT 
CLOSURe
Surgery has been the standard treatment of ventricular septal 
defects (VSDs) for decades. It has been shown to be effective 
and safe (38). However, with continuous development of novel 
occlusion devices, transcatheter VSD closure has become an 
effective alternative treatment modality in appropriately selected 
patients. The limitation of percutaneous VSD closure relates to 
the complexity of the defect and the proximity of the defect to 
adjacent structures, such as aortic, pulmonary, and tricuspid 
valves. In addition, those VSDs that are close to the membranous 
area, where the perforating branch of the conduction system lies 
underneath, closure with a high radial and compression force 
device may lead to the serious complication of permanent high-
grade atrio-ventricular block. During the early phase of transcath-
eter treatment for perimembranous (pm) VSDs, the eccentric 
Amplatzer membranous VSD occluder (St Jude Medical, MN, 
USA) was thought to be effective (39). However, the incidence 
of post-procedural complete heart block (6–6.5%) was higher 
than surgery (40, 41). Currently, transcatheter perimembranous 
ventricular septal defect (pmVSD) closure has not been approved 
in the US and many countries in Europe. However, in the East, 
a variety of available devices, which are matched to the different 
defect morphology and exert less pressure onto the ventricular 
septum (Figure 3), transcatheter pmVSD closure is considered 
to be acceptable efficacy, with low complication rates, especially 
complete heart block (incidence of 0–3%) (41–44). Recently, 
periventricular mini-thoracotomy VSD closure has emerged as 
a surgical alternative in China (45, 46). In the special circum-
stance of muscular or apical VSDs in infants or small children, 
working in close collaboration with surgeons, an interventional 
hybrid approach has become an attractive modality (22). Post 
myocardial infarction VSDs, where surgery may have been ruled 
out because of unacceptable high risk or in cases of postoperative 
residual shunt, percutaneous closure may be used (22).
FiGURe 4 | Angiographic pictures of PDA stenting from different 
approaches: (A) from femoral artery and (B) from right axillary artery.
FiGURe 5 | Pre- (A) and post-procedural (B) angiography of the right 
ventricular outflow tract (RvOT) stenting in neonatal tetralogy of 
Fallot with severe infundibular stenosis.
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Most cyanotic CHDs usually require surgery. Catheter 
intervention is a complementary approach to fulfill the optimal 
treatments in the following circumstances.
PDA STeNTiNG iN DUCT-DePeNDeNT 
PULMONARY CiRCULATiON DeFeCTS
Surgical systemic-to-pulmonary shunt (SPS), which mimicked 
the function of a PDA, has provided effective palliative treatment 
for duct-dependent pulmonary circulation defects for almost 
70  years. In the recent years, SPS has been more commonly 
performed in patients with more complex defects, such as single-
ventricle anatomy and pulmonary atresia than tetralogy of Fallot 
(TOF). In spite of wide clinical experience, neonatal mortality 
after SPS has ranged from 5 to 9% in the last two decades (47, 
48). Recently, from the United Kingdom national database, the 
early mortality rate was 9.8%. In addition, at 1.5  years, 13.9% 
of patients had died, and 17.8% needed shunt reintervention 
(49). This is probably a reflection of the more complex types of 
defects in whom SPS has been performed. Currently, with the 
availability of flexible and low profile coronary artery stents, duct 
stenting can be performed safely through a 4F–5F sheath, as an 
alternative to SPS (Figure 4). However, not all the ducts can be 
stented. The success rate of PDA stenting depends on the com-
plexity of the ductal morphology. Pulmonary atresia with intact 
ventricular septum is usually associated with a better chance of 
success with PDA stenting than the univentricular physiology 
or complex pulmonary atresia, in which the ductus arteriosus is 
usually tortuous (50, 51). Alwi and colleagues (52) reported an 
early mortality of 5.4% after ductal stenting with freedom from 
reintervention of 89% at 6 months and 55% at 12 months. It is 
reasonable to assume that none of the surgical and transcatheter 
palliative treatments for duct-dependent pulmonary circulation 
are perfect procedures. Both approaches have their own benefits 
and drawbacks, which require particular choice of the treatment 
in accordance with the particular defects, the availability of the 
devices, and the preference of the individual institution.
RiGHT veNTRiCULAR OUTFLOw  
TRACT STeNTiNG
Right ventricular outflow tract (RVOT) stenting has been an 
effective palliative therapy in hypercyanotic neonates and young 
infants with TOF, in whom surgical therapy is considered unsuit-
able or a high risk (Figure 5). Stenting may promote symmetrical 
growth of the pulmonary arteries without branch distortion as 
shown from the literatures of significant increase of pulmonary 
branch diameters (53–55). Also, in those babies in whom the 
obstruction is predominately at infundibular level and the 
pulmonary valve is well functioning, stenting of the RVOT with 
pulmonary valve sparing placement of the stent may improve the 
oxygen saturation without compromising of the right ventricular 
outflow performance and without causing free pulmonary 
regurgitation. Some months later, once the patient is ready for 
a definitive repair, the RVOT stent can be removed with limited 
technical surgical difficulties. However, a majority of the RVOT 
stented patients may require transannular patch because of the 
size of the pulmonary valve annulus (56).
HYBRiD PALLiATiON FOR HYPOPLASTiC 
LeFT HeART SYNDROMe AND COMPLeX 
SiNGLe veNTRiCLe
A combination of surgical and interventional catheterization as a 
targeted strategy, for example, by palliating a newborn with hypo-
plastic left heart syndrome (HLHS) using percutaneous ductal 
stenting (Figure 6) and bilateral branch pulmonary artery band-
ing, was first described in 1992 (57). The aim of this approach is 
to minimize complications of HLHS Norwood Stage I operation 
for high-risk patients (e.g., small patient size, severe ventricular 
dysfunction, severe tricuspid regurgitation, small ascending 
aorta size, and multisystem organ failure) or as a bridge to trans-
plantation. This strategy can also be performed in a variety of 
univentricular defects, in which systemic outflow or aortic arch 
FiGURe 6 | Angiography after the ductus arteriosus stenting in 
neonate with aortic valve atresia and hypoplastic aortic arch.
FiGURe 7 | Failing extra-cardiac Fontan circuit (A) treated by stenting 
of the hypoplastic left pulmonary artery (B) and diablo stenting of the 
restrictive fenestration (arrow) (C).
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appears hypoplastic (58, 59). Retrograde aortic arch  obstruction 
with the PDA fully open is considered a contraindication to the 
hybrid stage I palliation, since the struts of the implanted stent 
may acutely compromise retrograde coronary blood flow (22). 
Reintervention after hybrid palliation is relatively frequent and 
reduction of mortality remains an opportunity to improve. 
Recently, Murphy et  al. reported overall survival of 56.1% at a 
median follow-up of 32  months after hybrid palliation (59). 
Yerebakan et al. reported the follow-up results at 4.6 years after 
Giessen hybrid stage I palliation showing the operative mortality 
of hybrid stage I of 2.5%, comprehensive stage II of 4.9%, Fontan 
completion of 0%, and cumulative interstage mortality of 14.2% 
(60). The hybrid approach requires a novel mindset of collabora-
tion between surgeons and interventionists along with high-end 
hybrid surgical suite. Hybrid palliation is a strong foundation of 
further collaboration for treatments of other complex congenital 
and structural heart defects.
CATHeTeR iNTeRveNTiONS iN  
FONTAN CiRCULATiON
Surgical total cavopulmonary connection (TCPC), for the treat-
ment of tricuspid atresia, was first described in 1971 by Fontan 
et al. (61). At present, with several modifications of the surgical 
technique, TCPC is the definitive treatment for most univen-
tricular hearts. However, catheter intervention has become a 
major contributor pre-operatively or once these patients develop 
unstable hemodynamics, due to excessive pulmonary blood flow, 
low cardiac output, high venous pressure, progressive cyanosis, 
or obstruction in the pulmonary pathways. Pre-operative 
embolization of the excessive systemic-to-pulmonary collateral 
reduces the possibility of pulmonary hemorrhage and increased 
pulmonary arterial pressure due to overperfused lungs. Balloon 
angioplasty (BA) with or without stent implantation helps 
to create unobstructed pathways, which aim to optimize the 
pressures in this circuit (Figures  7A,B). Dilation or creation 
of a fenestration may stabilize the cardiac output in the early 
postoperative period (Figure 7C). In patients in whom cyanosis 
has persisted, occlusion of abnormal venous collaterals or previ-
ously created fenestration will improve systemic saturation. 
Completion of the Fontan or Glenn type of circulation may also 
be achieved percutaneously in carefully selected patients (62, 
63). In addition, taking down the Fontan by enlargement of the 
fenestration and occlusion of the conduit to pulmonary artery 
has been reported in patients with early failure of the Fontan 
circulation (64).
Stenosis of the valves or vessels can be treated percutaneously. 
However, surgery remains treatment of choice in small children, 
with complex anatomy, or with residual lesions, or those in whom 
complications may have occurred after an intervention.
PULMONARY vALvOPLASTY
Percutaneous balloon valvoplasty is feasible in most pulmonary 
valve stenosis patients (Figure 8). Post-procedural residual pres-
sure gradient is usually <30 mmHg in 68–92% of the patients 
with low incidence of major adverse events after the procedure 
(65, 66). Approximately 80% of the patients are free from 
reintervention over 10 years (67, 68). Pulmonary valve insuffi-
ciency developed in 10–40% after balloon valvoplasty (69). This 
incidence and the severity appear to be less than after surgery 
(70). Surgical valvotomy, however, is the mainstay of treatment 
in patients with mainly subvalvar, supravalvar, and multi-level 
of obstructions.
FiGURe 8 | Pre- (A), peri- (B), and post-procedural (C) angiography of the balloon pulmonary valvoplasty in neonatal critical pulmonary valve 
stenosis.
FiGURe 9 | Pre- (A), peri- (B), and post-procedural (C) angiography of the balloon aortic valvoplasty in neonate with severe aortic valve stenosis.
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AORTiC vALvOPLASTY
Balloon aortic valvoplasty is now considered a safe procedure 
although it is less predictable with regard to the outcomes 
compared with balloon pulmonary valvoplasty. From the most 
recent multicentre registries (29, 70), 61.5–71% of procedures 
achieved a residual gradient ≤35  mmHg after single-balloon 
aortic valvoplasty. Moderate-to-severe aortic regurgitation 
appeared in 17.4–19% after treatment, while unplanned cardiac 
surgery was needed in 1%. Neonatal balloon aortic valvoplasty 
and mixed obstructions are considered to be at high risk for 
complications, death, and suboptimal outcomes (70) (Figure 9). 
Surgical correction is indicated in patients who develop major 
complications, such as severe aortic regurgitation, or aortic cusp 
avulsion, or those who have a residual significant pressure gradi-
ent, or multi-level of obstruction, or when associated with other 
cardiac lesions.
TReATMeNT OF COARCTATiON  
OF THe AORTA
Surgery is accepted as an effective and preferred treatment 
in neonates and infants with coarctation of the aorta (COA) 
(71, 72). However, in older children or adults, surgical morbid-
ity is more frequent and may be detrimental (73, 74). BA has 
become an alternative treatment to surgery since 1983 (75, 76). 
Although the immediate results were relatively good, this 
procedure carries the risk of restenosis and aortic wall com-
plications, especially after BA in native COA patients (77–79). 
Currently, BA is recommended as the treatment of choice only 
for children with aortic re-coarctation (29). Stent technology 
has evolved rapidly over the past two decades. Stent implan-
tation is associated with effective outcomes in older children 
or adults with native or recurrent coarctation compared with 
surgery (74, 80–82). With open-cell stent design, complex 
coarctations can be treated safely without sacrificing the head 
and neck branches. Covered stents may be used to overcome 
or even prevent complications, such as aortic wall injury (83). 
With evolution of device technology, stent implantation in com-
plex anatomy, such as nearly or completely interrupted arch, or 
multi-level obstruction, is feasible with favorable outcomes (84) 
(Figure 10). However, stent therapy in infants and small chil-
dren with native COA has remained challenging for many years 
because of the need to expand the implanted stent to an adult 
size. Several breakable, over-dilatable, and biodegradable stents 
have been developed to overcome these limitations. Currently, 
stenting of native COA, even in small children, is feasible with 
excellent short-term outcomes (85–87).
STeNOSiS OF THe PULMONARY ARTeRY
Stenosis of the proximal pulmonary artery branches, which are 
proximal to the hilum of the lungs, can either be tackled by surgery 
FiGURe 10 | Pre- (A) and post-procedural (B) angiography of the 
covered CP stent implantation in the interrupted descending aorta: 
Courtesy of Nageswara Rao Konati.
FiGURe 11 | Bilateral pulmonary artery stenting in post Rastelli type 
operation for type i truncus arteriosus with severe bilateral proximal 
pulmonary branches stenosis. (A,B) Pre-procedure and (C,D) Post-stent 
implantation.
FiGURe 12 | Pre- and post-procedural angiography of the Melody 
valve implantation in post right ventricular outflow tract patch 
repaired pulmonary atresia with intact ventricular septum with severe 
pulmonary insufficiency (A) and venus P-valve implantation in post 
transannular patch repaired tetralogy of Fallot with severe pulmonary 
regurgitation (B).
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or catheter intervention. However, stenosis within the lung paren-
chyma can only be treated by endovascular approach, usually 
during catheterization or, less often, during hybrid surgery (88). 
Recurrent stenosis after surgery may occur in 35–40% of patients 
due to scar formation, distortion of the reconstructed vessels, 
or external compression (89, 90). In small children or patients 
with complex anatomy, primary BA may be used in severe main 
or branch pulmonary artery stenosis (22). However, in branch 
pulmonary artery stenoses, standard BA may have success rates 
of 50–60% with a recurrence rate of 15% and complication rate of 
6–12% (88, 90–92). High-pressure and cutting balloons improved 
the success rates, especially in younger patients with resistant 
lesions (93, 94). However, with continuous improvement of the 
stent technology, in most patients, stenting has become a treat-
ment of choice for branch pulmonary artery stenosis. Stents can 
be implanted effectively in patients with surgery-related stenosis, 
bifurcation stenosis, multi-level obstruction, or stenosis from the 
pressure effect of the adjacent structures (22, 95) (Figure  11). 
In growing children, however, they will require further dilation 
until the vessels reach adult diameter. In recurrent or complex 
stenoses, they usually need several attempts for pulmonary artery 
branch rehabilitation.
PeRCUTANeOUS PULMONARY  
vALve iMPLANTATiON
In order to accomplish complete bi-ventricular repair in various 
CHDs, such as tetralogy of Fallot, double outlet right ventricle, 
truncus arteriosus, or transposition of the great artery with 
ventricular septal defect, RVOT reconstruction with or without 
conduit replacement has been the mainstay of surgical treat-
ment for decades. However, most of these reconstructed RVOTs 
will eventually develop dysfunction, and multiple surgical 
 reinterventions may be needed during the lifetime of the patients 
(96, 97). Currently, percutaneous pulmonary valve implantation 
(PPVI) is considered an effective alternative treatment for  conduit 
dysfunction (97) (Figure 12A). However, with limitations of the 
available valve diameters and the size of delivery systems, current 
8Promphan and Qureshi Non-Surgical Treatment for Congenital Heart Disease
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